Search

Your search keyword '"Habibi, Anoosha"' showing total 540 results
Start Over Author "Habibi, Anoosha"
540 results on '"Habibi, Anoosha"'

1. Atrial arrhythmia in adults with sickle cell anemia: a missing link toward understanding and preventing strokes

Author

d’Humières, Thomas, Sadraoui, Zineb, Savale, Laurent, Boyer, Laurent, Guillet, Henri, Alassaad, Lara, de Luna, Gonzalo, Iles, Sihem, Balfanz, Paul, Habibi, Anoosha, Martino, Suella, Amorouayeche, Ziana, Dang, Thuy Linh, Pham Hung d'Alexandry d'Orengiani, Anne Laure, Rideau, Dominique, Train, Laura, Simon, Theo, Ibrahim, Christine, Messonnier, Laurent A., Audureau, Etienne, Derbel, Haytham, Calvet, David, Lellouche, Nicolas, Derumeaux, Geneviève, and Bartolucci, Pablo

Published
2024
Full Text
View/download PDF

3. The liver in sickle cell disease

Author

Duvoux, Christophe, Blaise, Lorraine, Matimbo, Jean-Jacques, Mubenga, Francky, Ngongang, Norbert, Hurtova, Monika, Laurent, Alexis, Augustin, Jérémy, Calderaro, Julien, Reizine, Edouard, Luciani, Alain, Habibi, Anoosha, Bachir, Dora, Vole, Geoffroy, Gellen-Dautremer, Justine, Leroy, Vincent, Levesque, Eric, and Bartolucci, Pablo

Published
2023
Full Text
View/download PDF

5. Determinants of ventricular arrhythmias in sickle cell anemia: toward better prevention of sudden cardiac death

Author

d’Humières, Thomas, Saba, Joseph, Savale, Laurent, Dupuy, Marie, Boyer, Laurent, Guillet, Henri, Alassaad, Lara, de Luna, Gonzalo, Iles, Sihem, Pham Hung d'Alexandry d'Orengiani, Anne L., Zaouali, Yosr, Boukour, Nouhaila, Pelinski, Yanis, Messonier, Laurent, Audureau, Etienne, Derbel, Haytham, Habibi, Anoosha, Lellouche, Nicolas, Derumeaux, Geneviève, and Bartolucci, Pablo

Published
2023
Full Text
View/download PDF

12. Fetal Hemoglobin Decrease During Voxelotor Treatment.

Author

De Luna, Gonzalo, Habibi, Anoosha, Moutereau, Stéphane, Martino, Suella, Alhamrouni, Jamila, Morel, Celia, Pelinski, Yanis, Zaouali, Yosr, Galactéros, Frédéric, and Bartolucci, Pablo

Abstract

ABSTRACT Voxelotor modifies hemoglobin‐oxygen affinity improving anemia and reducing hemolysis in sickle cell patients. However, the impact of Voxelotor on fetal hemoglobin (HbF) levels is unknown. We describe here variations of percentage of HbF measured by high performance liquid chromatography and mean corpuscular fetal Hb in a cohort of sickle cell patients treated with Voxelotor at Henri Mondor Sickle Cell Referral Center. Our data show a decrease in HbF levels in sickle cell patients after 6 months of treatment with Voxelotor, which is likely to be associated with an increase in the lifespan of red blood cells that are no longer prematurely removed from the circulation, particularly those with low HbF. This work raises the question of the risk of a rebound effect when stopping Voxelotor, which has a short half‐life, during the time it takes to increase HbF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complications (EXDRE): an open-label randomised controlled trial

Author

Habibi, Anoosha, Guillet, Emma, Gellen-Dautremer, Justine, Ribeil, Jean-Antoine, Arlet, Jean-Benoit, Mattioni, Sarah, Berkenou, Jugurtha, Delrieux, Noemie, Lionnet, François, Grenot, Jean-François, Mira, Jose, Peyrard, Arthur, Lacroix, Roxane, Garcin, Arnauld, Di Liberto, Gaetana, Hourdé, Christophe, Gellen, Barnabas, Messonnier, Laurent A, Galactéros, Frédéric, Audureau, Etienne, Merlet, Angèle N, Rupp, Thomas, Peyrot, Sandrine, Martin, Cyril, Féasson, Léonard, and Bartolucci, Pablo

Published
2018
Full Text
View/download PDF

14. Decreased risk of underdosing with continuous infusion versus intermittent administration of cefotaxime in patients with sickle cell disease and acute chest syndrome.

Author

Razazi, Keyvan, Berti, Enora, Cecchini, Jerome, Carteaux, Guillaume, Habibi, Anoosha, Bartolucci, Pablo, Arrestier, Romain, Gendreau, Ségolène, de Prost, Nicolas, Hulin, Anne, and Dessap, Armand Mekontso

Subjects
SICKLE cell anemia, CEFOTAXIME, ACUTE diseases, LENGTH of stay in hospitals, TEACHING hospitals
Abstract

Objective: Underdosing of antibiotics is common in patients with sickle cell disease (SCD). We hypothesized that in critically-ill patients with SCD receiving cefotaxime during acute chest syndrome, the continuous infusion may outperform the intermittent administration in achieving pharmacokinetic/pharmacodynamic targets. Design: Prospective before-after study. Settings: Intensive-care unit of a French teaching hospital and sickle cell disease referral center. Patients: Sixty consecutive episodes of severe acute chest syndrome in 58 adult patients with sickle cell disease. Interventions: Patients were treated with intermittent administration during the first period (April 2016 –April 2018) and with continuous infusion during the second period (May 2018 –August 2019). Measurements and main results: We included 60 episodes of acute chest syndrome in 58 patients (29 [25–34] years, 37/58 (64%) males). Daily dose of cefotaxime was similar between groups (59 [48–88] vs. 61 [57–64] mg/kg/day, p = 0.84). Most patients (>75%) presented a glomerular hyperfiltration with no difference between groups (p = 0.25). More patients had a cefotaxime trough level ≥2 mg/L with continuous infusion than intermittent administration: 28 (93%) vs. 5 (16%), p<0.001. The median residual concentration was higher in the continuous infusion than intermittent administration group: 10.5 [7.4–13.3] vs. 0 [0–0] mg/L, p<0.001. No infection relapse was observed in the entire cohort. Hospital length of stay was similar between groups. Conclusion: As compared to intermittent administration, continuous infusion of cefotaxime maximizes the pharmacokinetic/pharmacodynamic parameters in patients with SCD. The clinical outcome did not differ between the two administration methods; however, the study was underpowered to detect such a difference. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study.

Author

Gérardin, Marie, Rousselet, Morgane, Couec, Marie-Laure, Masseau, Agathe, Chantalat, Christelle, Driss, Françoise, Guitton, Corinne, Debbache, Karima, Foïs, Elena, Galacteros, Frédéric, Habibi, Anoosha, Léon, Anne, Mattioni, Sarah, Santin, Aline, Alexis-Fardini, Scylia, Augusty, Edima, Billaud, Marie, Divialle-Doumdo, Lydia, Etienne-Julan, Maryse, and Lemonne, Nathalie

Subjects
SUBSTANCE abuse, ANALGESICS, SICKLE cell anemia, GAS mixtures, NITROUS oxide, PSEUDOADDICTION, HOSPITAL patients
Abstract

Background: In many countries, nitrous oxide is used in a gas mixture (EMONO) for short-term analgesia. Cases of addiction, with significant misuse, have been reported in hospitalized patients. Patients suffering from sickle cell disease (SCD) could represent a high-risk population for substance use disorder (SUD) due to their significant pain crisis and repeated use of EMONO. The objective of the PHEDRE study was to assess the prevalence of SUD for EMONO in French SCD patients. Results: A total of 993 patients were included. Among 339 EMONO consumers, only 38 (11%) had a SUD, with very few criteria, corresponding mainly to a mild SUD due to a use higher than expected (in quantity or duration) and relational tensions with the care teams. Almost all patients (99.7%) were looking for an analgesic effect, but 68% of patients were also looking for other effects. The independent risks factors associated with at least one SUD criterion were: the feeling of effects different from the expected therapeutic effects of EMONO, at least one hospitalization for vaso occlusive crisis in the past 12 months and the presence of a SUD for at least one other analgesic drug. Conclusions: The use of EMONO was not problematic for the majority of patients. Manifestations of SUD that led to tensions with healthcare teams should alert and lead to an evaluation, to distinguish a true addiction from a pseudoaddiction which may be linked to an insufficient analgesic treatment related to an underestimation of pain in SCD patients. Trial registration: Clinical Trials, NCT02580565. Registered 16 October 2015, https://clinicaltrials.gov/ [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Is chest X‐ray still relevant for acute chest syndrome diagnosis?

Author

Pelinski, Yanis, Guindo, Aldiouma, Kassasseya, Christian, Diallo, Dapa, Arlet, Jean‐Benoît, Dessap, Armand Mekontso, Habibi, Anoosha, and Bartolucci, Pablo

Subjects
CHEST pain, X-rays, MEDICAL ethics, DIAGNOSIS, SICKLE cell anemia, SYNDROMES
Abstract

The article discusses the use of chest X-rays in diagnosing acute chest syndrome (ACS) in patients with sickle cell disease (SCD). The authors argue that chest X-rays may not be the most appropriate imaging tool for ACS diagnosis and propose the use of pulmonary auscultation as a robust diagnostic tool instead. They suggest an algorithm for ACS diagnosis based on lung auscultation, clinical severity, and the risk for pulmonary artery thrombosis. The authors emphasize the need to reduce radiation exposure and promote the use of ultrasound over X-rays, except for specific cases. [Extracted from the article]

Published
2024
Full Text
View/download PDF

19. Determinants of Ventricular Arrhythmias in Sickle Cell Anemia: Towards a Better Prevention of Sudden Cardiac Death

Author

d'Humières, Thomas, primary, Saba, Joseph, additional, Savale, Laurent, additional, Dupuy, Marie, additional, Boyer, Laurent, additional, Guillet, Henri, additional, Alassaad, Lara, additional, De Luna, Gonzalo, additional, Iles, Sihem, additional, Pham Hung d'Alexandry d'Orengiani, Anne-Laure, additional, Zaouali, Yosr, additional, Boukour, Nouhaila, additional, Pelinski, Yanis, additional, Messonnier, Laurent A., additional, Audureau, Etienne, additional, Derbel, Haytham, additional, Habibi, Anoosha, additional, Lellouche, Nicolas, additional, Derumeaux, Geneviève, additional, and Bartolucci, Pablo, additional

Published
2023
Full Text
View/download PDF

26. Immunological efficacy of pneumococcal vaccination including the 13-valent pneumococcal vaccine in adult patients with sickle-cell disease: results of the randomized DREVAC controlled trial

Author

Melica, Giovanna, primary, Bartolucci, Pablo, additional, Audureau, Etienne, additional, Le Corvoisier, Philippe, additional, Habibi, Anoosha, additional, Gellen, Justine, additional, Selmane, Dalia, additional, Michel, Marc, additional, Lacabaratz, Christine, additional, and Levy, Yves, additional

Published
2023
Full Text
View/download PDF

27. Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review

Author

Flevari, Pagona, primary, Voskaridou, Ersi, additional, Galactéros, Frédéric, additional, Cannas, Giovanna, additional, Loko, Gylna, additional, Joseph, Laure, additional, Bartolucci, Pablo, additional, Gellen-Dautremer, Justine, additional, Bernit, Emmanuelle, additional, Charneau, Corine, additional, and Habibi, Anoosha, additional

Published
2022
Full Text
View/download PDF

29. Impact of Transfusion Program during Pregnancy on the Obstetrical Outcomes in Sickle Cell Disease Women

Author

Habibi, Anoosha, primary, Lefebvre, Marion, additional, Sobcyk, Octavia, additional, Canouï-Poitrine, Florence, additional, Jebali, Amna, additional, De Luna, Gonzalo, additional, Bartolucci, Pablo, additional, Galactéros, Frédéric, additional, Pirenne, France, additional, Redel, Diane, additional, Boutin, Emmanuelle, additional, Haddad, Bassam, additional, and Lecarpentier, Edouard, additional

Published
2022
Full Text
View/download PDF

31. Renin‐angiotensin system blockade promotes a cardio‐renal protection in albuminuric homozygous sickle cell patients

Author

Haymann, Jean‐Philippe, Hammoudi, Nadjib, Stankovic Stojanovic, Katia, Galacteros, Frederic, Habibi, Anoosha, Avellino, Virginie, Bartolucci, Pablo, Benzerara, Yahia, Arlet, Jean‐Benoit, Djebbar, Morad, Letavernier, Emmanuel, Grateau, Gilles, Tabibzadeh, Nathalie, Girshovich, Alexei, Chaignon, Michel, Girot, Robert, Levy, Pierre, and Lionnet, Francois

Published
2017
Full Text
View/download PDF

33. Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial.

Author

Melica, Giovanna, Bartolucci, Pablo, Audureau, Etienne, Corvoisier, Philippe Le, Habibi, Anoosha, Gellen, Justine, Selmane, Dalia, Michel, Marc, Lacabaratz, Christine, and Levy, Yves

Subjects
STREPTOCOCCAL disease prevention, PNEUMOCOCCAL vaccines, VACCINE immunogenicity, STREPTOCOCCAL diseases, VACCINE effectiveness, RANDOMIZED controlled trials, SEROTYPES, DESCRIPTIVE statistics, RESEARCH funding, SICKLE cell anemia, DISEASE risk factors, EVALUATION, DISEASE complications, ADULTS
Abstract

Background Patients with sickle cell disease (SCD) are at high risk for invasive pneumococcal diseases. The immunological efficacy of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent polysaccharide vaccine (PPSV23) is poorly documented in adults with SCD. Methods This was a randomized open-labeled phase 2 study of the immunogenicity of PCV13 at week 0, followed by PPSV23 at week 4, compared with PPSV23 alone at week 4 in adult patients with SCD. The proportion of responders (4-fold increase in serotype-specific immunoglobulin [Ig] G antibodies) to ≥10 shared serotypes was assessed at week 8. Secondary end points were (1) geometric mean titers, (2) responders to 0–1, 2–5, 6–9, or 10–12 serotypes, (3) pneumococcal opsonophagocytic activity, and (4) response durability at weeks 24 and 96. Results In total, 128 patients were randomized in the PCV13/PPSV23 (n = 63) or PPSV23-alone groups (n = 65). At week 8, 24.56% and 8.20% of patients from the PCV13/PPSV23 and PPSV23 groups, respectively, reached the primary end point (P =.02). These numbers were 36.2% and 8.7% for opsonophagocytic activity responders (P =.002). A combined PCV13/PPSV23 strategy improved the breadth of responses to 0–1, 2–5, 6–9, or 10–12 serotypes with 15.8%, 35%, 24.6%, and 24.6% versus 52.5%, 31%, 8%, and 8% in the PPSV23 group. At week 96, geometric mean titers were significantly higher in the PCV13/PPSV23 than in the PPSV23-alone group for 5 serotypes (4, 14, 19A, 19F, 23F). Conclusions A PCV13/PPSV23 regimen improved the breadth and magnitude of antibody responses against a large range of pneumococcal serotypes in adults with SCD. The sustainability of the immune response requires recall strategies. Clinical Trial Registration: NCT02274415 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Acute-on-chronic liver failure due to severe intrahepatic vaso-occlusion and recurrence of the intial disease: 2 major features in liver transplantation for severe sickle-cell-related hepatopathy

Author

Duvoux, Christophe, primary, Mubenga, Francky, additional, Matimbo, Jean Jacques, additional, Blaise, Lorraine, additional, Levesque, Eric, additional, Merle, Jean Claude, additional, Ngongang, Norbert, additional, Gellen-Dautremer, Justine, additional, Carmagnat, Maryvonnick, additional, Galacteros, Frederic, additional, Cherqui, Daniel, additional, Leroy, Vincent, additional, Laurent, Alexis, additional, Habibi, Anoosha, additional, and Bartolucci, Pablo, additional

Published
2022
Full Text
View/download PDF

35. Blood exchange transfusion with dexamethasone and Tocilizumab for management of hospitalized patients with sickle cell disease and severe COVID ‐19: Preliminary evaluation of a novel algorithm

Author

De Luna, Gonzalo, primary, Habibi, Anoosha, additional, Odièvre, Marie‐Hélène, additional, Guillet, Henri, additional, Guiraud, Vincent, additional, Cougoul, Pierre, additional, Carpentier, Benjamin, additional, Loko, Gylna, additional, Guichard, Isabelle, additional, Ourghanlian, Clément, additional, Pawlotsky, Jean Michel, additional, Mahevas, Matthieu, additional, Limal, Nicolas, additional, Michel, Marc, additional, Mekontso‐Dessap, Armand, additional, Arlet, Jean‐Benoît, additional, and Bartolucci, Pablo, additional

Published
2022
Full Text
View/download PDF

36. Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study

Author

Forté, Stéphanie, primary, De Luna, Gonzalo, additional, Abdulrehman, Jameel, additional, Fadiga, Nafanta, additional, Pestrin, Olivia, additional, Pham Hung d’Alexandry d’Orengiani, Anne-Laure, additional, Aneke, John Chinawaeze, additional, Guillet, Henri, additional, Budhram, Dalton, additional, Habibi, Anoosha, additional, Ward, Richard, additional, Bartolucci, Pablo, additional, and Kuo, Kevin H. M., additional

Published
2022
Full Text
View/download PDF

39. Greffe cutanée en pastille dans les ulcères de jambe chez les patients drépanocytaires : une étude de cohorte multicentrique

Author

Hamann, Pierre, primary, Schourick, Jason, additional, Bureau, Jeanne-Marie, additional, Habibi, Anoosha, additional, Santin, Aline, additional, Mattioni, Sarah, additional, Bartolucci, Pablo, additional, Messas, Emmanuel, additional, Monfort, Jean-Benoit, additional, Barbaud, Annick, additional, Lionnet, François, additional, and Senet, Patricia, additional

Published
2021
Full Text
View/download PDF

40. Implementation of Escort-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study : Interests and Methodology

Author

de Montalembert, Mariane, primary, Voskaridou, Ersi, additional, Oevermann, Lena, additional, Cannas, Giovanna, additional, Habibi, Anoosha, additional, Loko, Gylna, additional, Joseph, Laure, additional, Colombatti, Raffaella, additional, Bartolucci, Pablo, additional, Brousse, Valentine, additional, and Galactéros, Frédéric, additional

Published
2021
Full Text
View/download PDF

41. Drepadom - Establishment of Home Care Services and Hospitalizations for Sickle Cell Disease Patients As Standard Care Since the Covid-19 Pandemic

Author

Pelinski, Yanís, primary, Mescam, Cindy, additional, Kassasseya, Christian, additional, De Luna, Gonzalo, additional, Guillet, Henri, additional, Noizat, Clara, additional, Lejeune, Sylvain, additional, Martino, Suella, additional, Bachir, Dora, additional, Driss, Françoise, additional, Jebali, Amna, additional, Pham Hung D'Alexandry D'Orengiani, Anne-Laure, additional, Lemonier, Nicolas, additional, Pirenne, France, additional, Habibi, Anoosha, additional, and Bartolucci, Pablo, additional

Published
2021
Full Text
View/download PDF

42. Causes and Circumstances of Death: Analysis in 266 Sickle Cell Adult Patients

Author

Habibi, Anoosha, primary, Ngo, Stephanie, additional, Razazi, Keyvan, additional, Audard, Vincent, additional, De Luna, Gonzalo, additional, Michel, Marc, additional, Pirenne, France, additional, Guillet, Henri, additional, Kassasseya, Christian, additional, Galactéros, Frédéric, additional, Mekontso-Dessap, Armand, additional, and Bartolucci, Pablo, additional

Published
2021
Full Text
View/download PDF

46. Nouveaux mécanismes de dysfonction endothéliale dans l’hémolyse intravasculaire

Author

Nguyen-Peyre, Kim-Anh, primary, Kiger, Laurent, additional, Decrouy, Xavier, additional, Vingert, Benoit, additional, Hocini, Hakim, additional, Lefebvre, Cécile, additional, Bencheikh, Laura, additional, Chadebech, Philippe, additional, Baudin-Creuza, Véronique, additional, Pakdaman, Sadaf, additional, Habibi, Anoosha, additional, Pirenne, France, additional, and Bartolucci, Pablo, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results